Pembrolizumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion ◦ Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection	Melanoma of skin Other specified malignant neoplasms of large intestine Malignant neoplasms of cervix uteri Adenocarcinoma of stomach Malignant neoplasms of oesophagogastric junction Squamous cell carcinoma of hypopharynx and variants Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx Squamous cell carcinoma of oropharynx Squamous cell carcinoma of nasopharynx Therapeutic equivalent to nivolumab for Melanoma of skin Renal cell carcinoma of kidney, except renal pelvis Carcinoma of breast, specialised type Squamous cell carcinoma of oesophagus Other specified malignant neoplasms of bronchus or lung